Photosynthetic dermal matrix for healing full-thickness skin wounds
Official title: Evaluation of the Efficacy of a Dermal Regeneration Matrix With Photosynthetic Microalgae for the Treatment of Patients With Full-Thickness Skin Wounds: Phase 2 Study
Run by Pontificia Universidad Catolica de Chile · NCT07157657 · Data updated 2026-11-12
This trial tests whether adding oxygen-producing microalgae to dermal scaffolds helps adults with acute or chronic full-thickness wounds heal faster and with fewer infections.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Pontificia Universidad Catolica de Chile Academic / other |
| Locations | 1 site (Santiago, RM) |
| Status | Recruiting |
| Started | June 24, 2025 |
| Main results expected | May 2028 |
| Study ends | May 2028 |
| Registry record updated | September 5, 2025 |
| Trial ID | NCT07157657 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with homogeneous acute or chronic full-thickness skin wounds sized 25–200 cm² who can consent and adhere to follow-up visits are the intended candidates.
✕Probably not a fit
Patients with wounds exposing bone, tendon, or major vessels, those with acute unrelated medical conditions, or individuals unable to adhere to the protocol are unlikely to benefit from this trial approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2, interventional trial compares standard dermal regeneration matrices (DRM) with identical matrices that contain photosynthetic microalgae (PDRM). Treatments are applied to randomly assigned areas of the same wound or to different wounds on the same patient, followed by autologous split-thickness skin grafting over the implanted matrices. Participants receive regular follow-up to track granulation tissue formation, infection rates, graft integration, and the quality of regenerated skin. The study enrolls adults with homogeneous full-thickness wounds between 25 and 200 cm² and uses within-patient comparisons to reduce variability.
Why it matters
Potential benefit: If successful, the photosynthetic matrix could speed wound granulation, improve graft integration, and lower local infection rates by supplying oxygen directly to the wound bed.
How similar studies have gone: Preclinical and early laboratory work on photosynthetic biomaterials have shown promise for improving oxygenation, but clinical evidence in humans is currently limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients covered by social insurance law or under the "Complementary Service Sales" (VSC) program, aged 18 years or older. * Presence of full-thickness skin wounds. * Wounds with homogeneous granulation tissue. * Wound size between 25 cm² and 200 cm². * Signed informed consent to participate in the study. Exclusion Criteria: * History of a psychiatric disorder that may impair decision-making or adherence to treatment. * Presence of an acute medical condition unrelated to the wound at the time of enrollment. * Wound with exposed bone, tendon, or major blood vessels. * Psychosocial conditions that may hinder adherence to the study protocol.
Where it's running
-
Hospital del Trabajador
Santiago, Rm, Chile Recruiting
Study contacts
- Study coordinator: Anil Sadarangani, PhD, MBA
- Email: asadaran@gmail.com
- Phone: +56-942766405
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.